First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)

被引：2

作者：

Angevin, Eric ^{[1
]}

Strickler, John ^{[2
]}

Weekes, Colin ^{[3
]}

Heist, Rebecca ^{[4
]}

Morgensztern, Daniel ^{[5
]}

Fan, Xiaolin ^{[6
]}

Olyaie, Ozzie ^{[6
]}

Motwani, Monica ^{[7
]}

Afar, Daniel ^{[6
]}

Naumovski, Louie ^{[6
]}

Kelly, Karen ^{[8
]}

机构：

[1] Gustave Roussy, Ditep, Villejuif, France

[2] Duke Univ, Med Ctr, Durham, NC USA

[3] Univ Colorado, Aurora, CO USA

[4] Massachusetts Gen Hosp, Children Canc Ctr, Boston, MA 02114 USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Abbvie Inc, Redwood City, CA USA

[7] Abbvie Inc, N Chicago, IL USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

来源：

关键词：

antibody drug conjugate; non-small cell lung cancer (NSCLC); c-Met; Erlotinib;

D O I：

10.1016/j.jtho.2016.11.449

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA09.09

引用

页码：S395 / S396

页数：2